Molecular target therapy for gastrointestinal stromal tumors

摘要: Gastrointestinal stromal tumors (GIST), the most common gastric mesenchymal tumor is unique due to presence of a driver mutation called c-kit and usage imatinib as targeted therapy. For resectable tumors, surgery preferred option patients with high-risk GIST are considered for adjuvant 3 years. The role neoadjuvant evolving. management metastatic GIST, FDA has approved imatinib, sunitinib regorafenib first, second third line therapy respectively. increased prevalence resistance paved way development multiple other secondary tertiary agents. We present brief review on pathophysiology pathways comprehensive various agents which have been developed treatment GIST.